Genetic determinants in HIV-1 Gag and Env V3 are related to viral response to combination antiretroviral therapy with a protease inhibitor

AIDS

Volumn 23, Issue 13, 2009, Pages 1631-1640

  Ho, Sarah K ^a   Perez, Elena E ^b   Rose, Stephanie L ^a   Coman, Roxana M ^a   Lowe, Amanda C ^a   Hou, Wei ^a   Ma, Changxing ^c   Lawrence, Robert M ^a   Dunn, Ben M ^a   Sleasman, John W ^b   Goodenow, Maureen M ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

Antiretroviral therapy response; Coreceptors; HIV 1 Env V3; HIV 1 Gag; HIV 1 protease inhibitors

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; ENVELOPE PROTEIN; GAG PROTEIN; INDINAVIR; PROTEIN ENV V3; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADOLESCENT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN CLEAVAGE; SCHOOL CHILD; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRAL GENETICS; VIRUS REPLICATION; VIRUS RESISTANCE;

ADOLESCENT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, MULTIPLE, VIRAL; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENETIC MARKERS; GENETIC VARIATION; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INFANT; LONGITUDINAL STUDIES; PEPTIDE FRAGMENTS; PHYLOGENY; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 69449106744     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32832e0599     Document Type: Article

References (47)

1. Quinones-Mateu ME, Arts EJ. HIV-1 fitness: implications for drug resistance, disease progression, and global epidemic evolution. In: Kuiken C, Foley B, Hahn B, Marx P, McCutchan F, Mellors JW,et al. editors. HIV Sequence Compendium 2001 Los Alamos, New Mexico, USA: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory; 2001. pp. 134-170.
2. Martinez-Picado J, Prado JG, Fry EE, Pfafferott K, Leslie A, Chetty S, et al. Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J Virol 2006; 80:3617-3623.
3. Doyon L, Croteau G, Thibeault D, Poulin F, Pilote L, Lamarre D. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J Virol 1996; 70:3763-3769. (Pubitemid 26161824)
4. Mammano F, Petit C, Clavel F. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. J Virol 1998; 72:7632-7637. (Pubitemid 28377901)
5. Zhang YM, Imamichi H, Imamichi T, Lane HC, Falloon J, Vasudevachari MB, et al. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J Virol 1997; 71:6662-6670. (Pubitemid 27355324)
6. Goodenow MM, Bloom G, Rose SL, Pomeroy SM, O'Brien PO, Perez EE, et al. Naturally occurring amino acid polymorphisms in human immunodeficiency virus type 1 (HIV-1) Gag p7(NC) and the C-cleavage site impact Gag-Pol processing by HIV-1 protease. Virology 2002; 292:137-149. (Pubitemid 34925846)
7. Whitehurst N, Chappey C, Petropoulos C, Parkin N, Gamarnik A. Polymorphisms in p1-p6/p6M of HIV type 1 can delay protease autoprocessing and increase drug susceptibility. AIDS Res Hum Retroviruses 2003; 19:779-784. (Pubitemid 37215133)
8. Ho SK, Coman RM, Bunger JC, Rose SL, O'Brien P, Munoz I, et al. Drug-associated changes in amino acid residues in Gag p2, p7(NC), and p6(Gag)/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response. Virology 2008; 378:272-281.
9. Nijhuis M, van Maarseveen NM, Lastere S, Schipper P, Coakley E, Glass B, et al. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS Med 2007; 4:e36. (Pubitemid 46191830)
10. Maguire MF, Guinea R, Griffin P, Macmanus S, Elston RC, Wolfram J, et al. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro. J Virol 2002; 76:7398-7406. (Pubitemid 34760962)
11. Aquaro S, Perno CF, Balestra E, Balzarini J, Cenci A, Francesconi M, et al. Inhibition of replication of HIV in primary monocyte/macrophages by different antiviral drugs and comparative efficacy in lymphocytes. J Leukoc Biol 1997; 62:138-143. (Pubitemid 27321752)
12. Aquaro S, Calio R, Balzarini J, Bellocchi MC, Garaci E, Perno CF. Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir. Antivir Res 2002; 55:209-225. (Pubitemid 34718126)
13. Briggs DR, Tuttle DL, Sleasman JW, Goodenow MM. Envelope V3 amino acid sequence predicts HIV-1 phenotype (co-receptor usage and tropism for macrophages). AIDS 2000; 14:2937-2939.
14. Hwang SS, Boyle TJ, Lyerly HK, Cullen BR. Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 1991; 253:71-74.
15. Goodenow MM, Collman RG. HIV-1 coreceptor preference is distinct from target cell tropism: a dual-parameter nomenclature to define viral phenotypes. J Leukoc Biol 2006; 80:965-972.
16. Brumme ZL, Dong WW, Yip B, Wynhoven B, Hoffman NG, Swanstrom R, et al. Clinical and immunological impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy. AIDS 2004; 18:F1-F9. (Pubitemid 38393456)
17. Galan I, Jimenez JL, Gonzalez-Rivera M, De Jose MI, Navarro ML, Ramos JT, et al. Virological phenotype switches under salvage therapy with lopinavir-ritonavir in heavily pretreated HIV-1 vertically infected children. AIDS 2004; 18: 247-255. (Pubitemid 38253447)
18. Skrabal K, Trouplin V, Labrosse B, Obry V, Damond F, Hance AJ, et al. Impact of antiretroviral treatment on the tropism of HIV-1 plasma virus populations. AIDS 2003; 17:809-814. (Pubitemid 36547652)
19. Perez EE, Rose SL, Peyser B, Lamers SL, Burkhardt B, Dunn BM, et al. Human immunodeficiency virus type 1 protease genotype predicts immune and viral responses to combination therapy with protease inhibitors (PIs) in PI-naive patients. J Infect Dis 2001; 183:579-588. (Pubitemid 32147514)
20. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV. MMWR Recomm Rep 2002; 51 (RR-7):1-55.
21. Mueller BU, Sleasman J, Nelson RP Jr, Smith S, Deutsch PJ, Ju W, et al. A phase I/II study of the protease inhibitor indinavir in children with HIV infection. Pediatrics 1998; 102 (1 Pt 1):101-109. (Pubitemid 28309253)
22. Mueller BU, Nelson RP Jr, Sleasman J, Zuckerman J, Heath-Chiozzi M, Steinberg SM, et al. A phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection. Pediatrics 1998; 101 (3 Pt 1):335-343. (Pubitemid 28136403)
23. Ghaffari G, Passalacqua DJ, Caicedo JL, Goodenow MM, Sleasman JW. Two-year clinical and immune outcomes in human immunodeficiency virus-infected childrenwho reconstitute CD4 T cells without control of viral replication after combination antiretroviral therapy. Pediatrics 2004; 114:e604-e611. (Pubitemid 41647669)
24. Rodriguez CA, Koch S, Goodenow M, Sleasman JW. Clinical implications of discordant viral and immune outcomes following protease inhibitor containing antiretroviral therapy for HIV-infected children. Immunol Res 2008; 40:271-286. (Pubitemid 351903816)
25. Barrie KA, Perez EE, Lamers SL, Farmerie WG, Dunn BM, Sleasman JW, et al. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1. Virology 1996; 219:407-416. (Pubitemid 26188390)
26. Tuttle DL, Anders CB, Aquino-De Jesus MJ, Poole PP, Lamers SL, Briggs DR, et al. Increased replication of nonsyncytium-inducing HIV type 1 isolates in monocyte-derived macrophages is linked to advanced disease in infected children. AIDS Res Hum Retroviruses 2002; 18:353-362.
27. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, et al. Update of the Drug Resistance Mutations in HIV-1: Spring 2008. Top HIV Med 2008; 16:62-68.
28. Swofford L, Sullivan JL. Phylogeny inference based on parsimony and other methods with PAUPM. In: The Phylogenetic Handbook: a practical approach to DNA and protein phylogeny. New York: Cambridge University Press; 2003. pp. 160-206.
29. Hoffman NG, Schiffer CA, Swanstrom R. Covariation of amino acid positions in HIV-1 protease. Virology 2003; 314:536-548. (Pubitemid 37206360)
30. Bickel PJ, Cosman PC, Olshen RA, Spector PC, Rodrigo AG, Mullins JI. Covariability of V3 loop amino acids. AIDS Res Hum Retroviruses 1996; 12:1401-1411.
31. Jensen MA, Li FS, 't Wout AB, Nickle DC, Shriner D, He HX, et al. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol 2003; 77:13376-13388.
32. Milich L, Margolin B, Swanstrom R. V3 loop of the human immunodeficiency virus type 1 Env protein: interpreting sequence variability. J Virol 1993; 67:5623-5634. (Pubitemid 23241399)
33. Resch W, Hoffman N, Swanstrom R. Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks. Virology 2001; 288:51-62. (Pubitemid 32846473)
34. Bally F, Martinez R, Peters S, Sudre P, Telenti A. Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors. AIDS Res Hum Retroviruses 2000; 16:1209-1213. (Pubitemid 30679926)
35. Bloom G, Perez E, Parikh S, Kay J, Mills J, Goodenow M, et al. A comparison of gag-pol precursor cleavage in naturally arising HIV variants. Adv Exp Med Biol 1998; 436:53-57. (Pubitemid 28201265)
36. Brown AJ, Korber BT, Condra JH. Associations between amino acids in the evolution of HIV type 1 protease sequences under indinavir therapy. AIDS Res Hum Retroviruses 1999; 15:247-253.
37. Koch N, Yahi N, Fantini J, Tamalet C. Mutations in HIV-1 gag cleavage sites and their association with protease mutations. AIDS 2001; 15:526-528. (Pubitemid 32207574)
38. Wu TD, Schiffer CA, Gonzales MJ, Taylor J, Kantor R, Chou S, et al. Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. J Virol 2003; 77:4836-4847. (Pubitemid 36402833)
39. Yahi N, Tamalet C, Tourres C, Tivoli N, Ariasi F, Volot F, et al. Mutation patterns of the reverse transcriptase and protease genes in human immunodeficiency virus type 1-infected patients undergoing combination therapy: survey of 787 sequences. J Clin Microbiol 1999; 37:4099-4106.
40. + T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis 2000; 181:946-953.
41. Essajee SM, Kim M, Gonzalez C, Rigaud M, Kaul A, Chandwani S, et al. Immunologic and virologic responses to HAART in severely immunocompromised HIV-1-infected children. AIDS 1999; 13:2523-2532. (Pubitemid 30038030)
42. Sleasman JW, Nelson RP, Goodenow MM, Wilfret D, Hutson A, Baseler M, et al. Immunoreconstitution after ritonavir therapy in children with human immunodeficiency virus infection involves multiple lymphocyte lineages. J Pediatr 1999; 134:597-606. (Pubitemid 30180600)
43. - CD11a(bright) activated T cells. J Allergy Clin Immunol 2008; 122:166-172; 172.
44. Abecasis AB, Deforche K, Bacheler LT, McKenna P, Carvalho AP, Gomes P, et al. Investigation of baseline susceptibility to protease inhibitors in HIV-1 subtypes C, F, G and CRF02-AG. Antivir Ther 2006; 11:581-589. (Pubitemid 44277423)
45. Holguin A, Paxinos E, Hertogs K, Womac C, Soriano V. Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes. J Clin Virol 2004; 31:215-220. (Pubitemid 39311801)
46. Vergne L, Stuyver L, Van HM, Butel C, Delaporte E, Peeters M. Natural polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-naive patients. J Clin Virol 2006; 36:43-49. (Pubitemid 44382730)
47. Coman RM, Robbins AH, Fernandez MA, Gilliland CT, Sochet AA, Goodenow MM, et al. The contribution of naturally occurring polymorphisms in altering the biochemical and structural characteristics of HIV-1 subtype C protease. Biochemistry 2008; 47:731-743.